| Literature DB >> 28579766 |
Lenore Dedeyne1, Mieke Deschodt2,3,4, Sabine Verschueren5, Jos Tournoy1,3, Evelien Gielen1,3.
Abstract
BACKGROUND: Frailty is an aging syndrome caused by exceeding a threshold of decline across multiple organ systems leading to a decreased resistance to stressors. Treatment for frailty focuses on multi-domain interventions to target multiple affected functions in order to decrease the adverse outcomes of frailty. No systematic reviews on the effectiveness of multi-domain interventions exist in a well-defined frail population.Entities:
Keywords: cognition; exercise; hormone; nutrition; older adults; social; supplement; vulnerable
Mesh:
Year: 2017 PMID: 28579766 PMCID: PMC5448695 DOI: 10.2147/CIA.S130794
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1Flow chart of study selection process.
Study characteristics
| Study | Country | Study participants | Duration of the intervention | Measurements
| Study design | N | Frailty diagnostic tool | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention period
| Follow-up period
| |||||||||||
| Pre | 3 months before end of intervention | Post (0 months) | 3–4 months | 6 months | 9 months | |||||||
| Chan et al | Taiwan | (Pre)frail, men and women, aged 71.4 (±3.7) | 3 months | * | * | * | * | RCT | 117 | 3–6 on The Chinese Canadian Study of Health and Aging Clinical Frailty Scale Telephone Version AND ≥1 of modified Fried frailty phenotype criteria | ||
| Chin A Pawet al | The Netherlands | Frail, men and women, aged 79 | 17 weeks | * | * | RCT | 112–161 | Modified Chin A Paw frailty definition | ||||
| Hennessey et al | United States | Moderately frail, men and women, aged 71.3 (±4.5) | 6 months | * | * | RCT | 31 | Physical performance test (PPT): score (12–28)/36 | ||||
| Ikeda et al | Japan | (Pre)frail, men and women, aged 78.4±7.8 and 80.4±8.9 | 3 months | * | * | Cross-over | 52 | Fried frailty phenotype criteria | ||||
| Kenny et al | United States | Frail, women, aged 76.6 (±6.0) | 6 months | * | * | RCT | 99 | At least 1 of 5 Fried frailty criteria: population is at least prefrail | ||||
| Kim et al | Japan | Frail, women, aged 75+ | 3 months | * | * | * | RCT | 131 | At least 3 of the modified Fried frailty phenotype criteria | |||
| Kwon et al | Japan | Prefrail, women, aged 76.8 | 3 months | * | * | * | RCT | 89 | Modified Fried frailty phenotype criteria | |||
| Luger et al | Austria | (Pre)frail, men and women, aged 82.8(±8.0) | 12 weeks | * | * | RCT | 80 | Prefrail or frail according to Frailty Instrument for Primary Care of the Survey of Health, Ageing, and Retirement in Europe (SHARE-FI) | ||||
| Ng et al | Singapore | (Pre)frail, men and women, aged 70.0 (±4.7) | 6 months | * | * | * | * | RCT | 246 | Fried frailty phenotype criteria | ||
| Rydwik et al | Sweden | Frail, men and women, aged 83.3(±4.0) | 9 months | * | * | * | RCT | 96 | Modified Chin A Paw frailty definition | |||
| Tarazona-Santabalbina et al | Spain | Frail, men and women, aged 70+ | 24 weeks | * | * | RCT | 100 | Fried frailty phenotype criteria | ||||
| Tieland et al | The Netherlands | (Pre)frail, men and women, aged 78(±1.0) | 24 weeks | * | * | RCT | 62 | 1–2 (prefrail) or at least 3(frail) of the Fried frailty phenotype criteria | ||||
Notes:
Reported mean age of largest study group.
Chan et al: 3/6 on the CCSHA_CFS_TV84,85 for first-stage screening. CHS-PCF5 with modifications: weight loss of 3 kg instead of 5 kg; Taiwan international physical activity questionnaire short form instead of the Minnesota Leisure time physical activity questionnaire86 to measure energy expenditure.
Chin A Paw et al and Rydwik et al: Physical activity in combination with weight loss is used as an effective screening criterion for identifying frailty.87 The first criterion, inactivity, is defined as not participating regularly in physical activities of moderate to high intensity, defined as >30 minutes of brisk walking, cycling, or gymnastics weekly in Chin A Paw et al, and as ≤ grade 3/6 scale of physical activity88,89 in Rydwik et al. The second criterion is involuntary weight loss (≥5% in Rydwik et al) or a BMI below 25 kg/m2 (Chin A Paw et al) or below 20 kg/m2 (Rydwik et al) or more, based on self-reported height and weight.
Hennessey et al: PPT, developed by Reuben was used, frail participants were defined as those with PTT score between 12 and 28 of a total possible score of 36.90
Ikeda et al, Kenny et al, Ng et al, Tarazona-Santabalbina et al, and Tieland et al: (Pre)frailty according to the Fried Frailty phenotype.5
Kim et al: Frailty according to CHS-PCF5 with modifications: weight loss of 2–3 kg instead of 5 kg; 1–1.5 kg after 3 months intervention or 1.3–2 kg after 4 months follow-up; Grip strength less than 19 kg; walking speed <1 m/s; low activity: answering “true” to at least 3 of the following 4 statements “I regularly take walks less than once a week,” “I do not exercise regularly,” “I do not actively participate in hobbies or lessons of any sort,” and “I do not participate in any social groups for elderly people or volunteering.”
Kwon et al: Based on CHS-PCF,5 Frailty: lowest 20th percentile on handgrip strength and walking ability among the total participants; Prefrailty: muscle weakness (handgrip strength in lowest quartile at baseline, ≤23 kg) and slow gait speed (lowest quartile of times usual walking speed at baseline, ≤1.52 m/s).
Luger et al: (Pre)frail according to the SHARE-FI.91
Abbreviations: RCT, randomized controlled trial; CCSHA_CFS_TV, Chinese Canadian Study of Health and Aging Clinical Frailty Scale Telephone Version; CHS-PCF, Cardiovascular Health Study Phenotypic Classification of Frailty; BMI, body mass index; PPT, Physical performance test; SHARE-FI, Frailty Instrument for Primary Care of the Survey of health, Ageing, and Retirement in Europe.
Methodological quality assessment of the included studies
| Study | Clearly stated aim | Inclusion of consecutive patients | Prospective collection of data | Endpoints appropriate to study aim +ITT | Unbiased assessment of study endpoint(s) | Follow-up period appropriate to study aim | Loss to follow-up <5% | Prospective study size calculation | Adequate control group | Contemporary groups | Baseline equivalence of groups | Adequate statistical analyses | Total score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chan et al | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | |
| Chin A Paw et al | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 1 | |
| Hennessey et al | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 0 | 2 | 2 | 0 | 1 | |
| Ikeda et al | 2 | 0 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | |
| Kenny et al | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | |
| Kim et al | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Kwon et al | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | |
| Luger et al | 2 | 2 | 2 | 2 | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | |
| Ng et al | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | |
| Rydwik et al | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | |
| Tarazona-Santabalbina et al | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | |
| Tieland et al | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
Notes: 0, not reported; 1, reported but inadequate; 2, reported and adequate.
Abbreviation: ITT, intention-to-treat analyses; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuAd, nutritional advise; NuMF, nutritional supplementation of MFGM; MFGM, milk fat globule membrane; PS, problem-solving therapy.
Intervention characteristics
| Study | Exercise intervention
| Nutritional intervention
| Other intervention
| Control intervention
| Compliance | ||||
|---|---|---|---|---|---|---|---|---|---|
| Content | Frequency | Content | Frequency | Content | Frequency | Content | Frequency | ||
| Chan et al | Warm up (brisk walk, stretching major joints and muscles), resistance training, postural control activities, and balance training, cool down (relaxation) Resistance weights: rubber band and water (0.6–1 L); intensity not reported | 3×/week 60 min | Nutritional consultation: possibility to ask dietary questions, assess dietary compliance = NuAd | During exercise session | – Problem-solving therapy: solve problems contributing to mood-related conditions, increase self-efficacy | 2×/month problem-solving therapy | Non-Ex and NuAd and non- PS: how much they read the booklet and how well they complied with suggested diet and exercise protocols described in educational booklets | 1×/month | Ex + Nu: 18/55 participants attended at least 50% of the 36 intervention sessions PST: 17/57 completed the 6 courses |
| Chin A Paw et al and de Jong et al | Warm-up (walking and exercise- to-music routines), skills training (strength training with 450 g wrist and ankle weights, speed, flexibility, coordination, endurance) to perform and sustain motor actions (reaching, throwing, catching, kicking, etc), cool down (stretching and relaxation) Gradually increased intensity: train at intensity between 6 and 8 on a 10-point perceived exertion scale | 2×/week 45 min | Supplementation: fruit and dairy products enriched with vitamins and minerals at 25%–100% of recommended dietary allowance = NuP + NuVM | 1 fruit and 1 dairy product/day | = PS | Exercise: social program (lectures, social activities, and crafts) Home visit for supply of fresh food products Nutritional: same foods as intervention group but not enriched (= NuP) | 1×/2 weeks 90 min | Ex: attendance: 90% (range 47%–100%) Nu: high compliance: percentage of participants with at least one deficiency decreased from 61% to 15% Control: attendance: 80% (range 50%–100%) | |
| Hennessey et al | Warm-up, low impact graded resistance training, cool down. Knee extension and ankle dorsiflexion: W1–5: 20%–60% 1 RM; W6–9: 80%–90% 1 RM; W10–17 & W18–25: 60%–95% retested 1 RM Plantar flexion: weights 5%–10% of body weight or quadriceps strength and progress 2%–5% every 2 weeks | 3×/week 60 min | Growth hormone: rhGH (sc) 0.0025–0.0037 mg/kg = Hor | 1×/day | Hormone: placebo injections | 1×/day | Not reported | ||
| Ikeda et al | Muscle strength exercise (intensity: 30% of MVC; 3 sets of 20 repetitions), aerobic exercise (intensity 12 on BRP), balance exercise, cool down | 2×/week | 6 g Branched-chain amino acid (BCAA) supplementation (1,560 mg BCAA; 1,440 mg essential AA) = NuP | 2×/week within 10 min before exercise | Nutritional: maltodextrin (MD) | 2×/week within 10 min before exercise | Ex: compliance rate ≥95% Nu: compliance rate 100% | ||
| Kenny et al | Yoga (Ivengar): breathing exercises, postures focusing on balance and stretching, relaxation; progressive difficulty OR Chair aerobics: commercially available tapes of moderate aerobic effort, increasing difficulty from week 4–6 onwards Intensity not reported = Ex | 2×/week 90 min 2×/week 90 min | All participants: 630 mg calcium and 400 IU cholecalciferol = NuVM | 1×/day | Hormone: 50 mg/day DH EA = Hor | 1×/day | Hormone: placebo | 1×/day | Ex: 73.1%±24.2% adherence DHEA/placebo: 88.9%±22.4% adherence |
| Kim et al | Warm-up, progressive strengthening exercises (with Thera bands, increasing repetitions), balance and gait training, cool down Moderate intensity: 12–14 on BRP | 2×/week 60 min | 6 pills with each 167 mg MFGM (21% protein; 44% fat; 26.5% carbohydrate, 33.3% phospholipids) = NuMF | 1×/day morning | Nutritional: placebo with similar shape, taste and texture but whole milk powder instead of MFGM (26.3% protein; 25.2% fat; 39.5% carbohydrate, 0.286% phospholipids) = NuP | 1×/day morning | Not reported | ||
| Kwon et al | Warm up, stretching exercises, exercises aiming to increase muscle strength and balance capability, cool down | 1×/week 60 min | – Nutritional education: lecture | 1×/week | General health education session: | 1×/month | Not reported | ||
| Luger et al | Warm-up and strength training(6 exercises, 2 sets of 15 repetitions until muscular exhaustion) + physical education | 2(−3) ×/week 30 min | Dietary discussions: how to enrich food with protein, recipes, healthy for life plate | 2×/week | Portfolio of possible activities(go out, have a chat, and sharing interests), especially cognitive training | 2×/week | Mean adherence rate for recommended 20 home visits | ||
| Ng et al | Strength and balance training. Resistance training integrated with functional tasks | 2×/week90 min | Supplementation: | 1×/day | Cognition: engage in cognitive-enhancing activities to stimulate short-term memory, enhance attention and information-processing skills, and reasoning and problem-solving abilities | First 12 weeks: | – General: one standard care from health and aged care services | 1×/day | Mean compliance levels: Ex: 85% |
| Rydwik et al | Warm-up (aerobic training), progressive muscle strength training (W1-2: 60% 1 RM; at W3: 80% 1 RM; 1 RM measurement was repeated at W6 and W10), Qigong balance training, cool down Weights: 10%–20% of body weight | 2×/week 60 min | – Individual dietary counseling based on baseline food record data | 1× in total 60 min | General advice regarding physical activity and nutrition for the elderly | Ex: mean compliance rate was 65% (4%–100%) Nu: mean compliance rate was 73% (20%–100%) | |||
| Tarazona- Santabalbina et al | Proprioception and balance exercises, aerobic training (initially 40% of maximum heart rate to 65%), strength(initially 25% of 1 RM to 75%), stretching | 5×/week 65–70 min | Nutritional information of the optimal energy intake, the requirement to ensurea minimal protein intake of 0.8 g/kg body weight. Calcidol levels <30 ng/mL: calcidol loading dose. | 1×/day | Nutritional: identical | 1×/day | Ex: 47.3% (95% CI 38.7%–55.7%) | ||
| Tieland et al | Warm up, resistance exercises at increasing intensity (50%[10–15 repetitions] – to 75%[8–10 repetitions] of 1 RM).1 RM measurement was repeated after 4, 8, 12, 16, and 20 weeks of training | 2×/week | Supplementation: 250 mL protein supplemented beverage with 15 g protein, 7.1 g lactose, 0.5 g fat, 0.4 g calcium= NuP + NuVM | 2×/day: after breakfast and after lunch | Nutritional: placebo drink without protein, 7.1 g lactose, 0.4 g calcium | 2×/day | Average adherence ≥98% and not different between the groups | ||
Abbreviations: RM, repetition maximum; Vit, vitamin; rhGH, recombinant human growth hormone; sc, subcutaneous; MFGM, milk fat globule membrane; HRT, hormone replacement therapy; CE, conjugated estrogens; MPA, medroxyprogesterone acetate; DHEA, dehydroepiandrosterone; min, minutes; Hor, hormonal intervention; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuAd, nutritional advise; NuMF, nutritional supplementation of MFGM; PS, problem-solving therapy; BRP, Borg Rate of Perceived Exertion scale; MVC, maximal voluntary contraction; CI, confidence interval; W, week; AA, amino acid.
Frailty outcomes
| Study | Outcome | 3 months before end of intervention | Post-intervention (0 m) | 3–4 m FU | 6 m FU | 9 m FU |
|---|---|---|---|---|---|---|
| Kim et al | Frailty status | / | Ex + NuMF (OR =3.12, CI =1.13; 8.60): significantly improved compared to NuP group | Ex + NuP (OR =3.64, CI =1.12; 11.85) and Ex + NuMF (OR =4.67, CI =1.45; 15.08): significantly improved compared to NuP group | / | / |
| Frailty score | / | / | Ex + NuMF and Ex + NuP: significantly improved | / | / | |
| Ng et al | Frailty status | / | / | / | Significantly improved compared to control group: | / |
| Frailty score | Significantly improved compared to control group (mean change = −0.47 [− 0.75; −0.19]): | Significantly improved compared to control group (mean change =−0.34 [CI =−0.63; −0.06]): | Significantly improved compared to control group (mean change = −0.14 [CI = −0.43; −0.14]): | |||
| Chan et al | Frailty status | / | Ex + NuAd + PS and Ex + NuAd (45%): significantly improved | NS | / | NS |
| Luger et al | Frailty status | / | NS | / | / | / |
| Tarazona-Santabalbina et al | Frailty score | / | Ex + NuAd + NuVM (FFC: 1.6±0.9) (EFS: 7.7±2.0): significantly improved | / | / | / |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated. Frailty score: number of frailty criteria (out of five); frailty status: frail, prefrail, or robust.
P<0.05;
P<0.01;
P<0.001.
Abbreviations: FFC, Fried frailty criteria; EFS, Edmonton frailty scale; m, months; FU, follow-up; Hor, hormone; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuMF, nutritional supplementation of milk fat globule membrane; PS, psychosocial intervention; NS, no significant difference; /, not available; kg, kilogram; CI, 95% confidence interval; SD, standard deviation.
Muscle mass
| Study | Outcome and method | 3 months before end of intervention | Post-intervention (0 m) | 4 m FU | 6 m FU | 9 m FU |
|---|---|---|---|---|---|---|
| Kim et al | Appendicular skeletal mass (kg); DXA | / | NS | NS | / | / |
| Tieland et al | Lean mass (kg); DXA | / | Treatment × time interactions: Ex + NuP + NuVM: significantly improved compared to Ex group for appendicular | / | / | / |
| Chin A Paw et al | Lean body mass (kg); DXA | / | Ex + NuP + NuVM and Ex (+0.5 kg): significantly improved | / | / | / |
| Tarazona-Santabalbina et al | Lean mass (kg); BIA | / | NS | / | / | / |
| Kenny et al | Total and regional lean tissue mass (kg); DXA | / | Appendicular skeletal muscle mass: NS; Lean mass: Ex + NuVM + Hor (39.6±6.1 kg): significantly improved | / | / | / |
| Rydwik et al | FFM (kg); body weight minus fat mass (sum of four skin folds) | / | NS | / | NS | / |
| Chan et al | FFM (kg); BIA method | / | / | / | / | NS |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05;
P<0.01;
P<0.001.
Abbreviations: DXA, dual X-ray absorptiometry; BIA, bioelectrical impedance analysis; FFM, fat-free mass; m, months; FU, follow-up; Hor, hormone; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuMF, nutritional supplementation of MFGM; PS, psychosocial intervention; NS, no significant difference; /, not available; kg, kilogram; CI, 95% confidence interval; SD, standard deviation.
Muscle strength
| Study | Strength | 3 months before end of intervention | Post-intervention (0 m) | 4 m FU | 6 m FU |
|---|---|---|---|---|---|
| Kim et al | Upper | / | NS | NS | / |
| Ex + NuP/NuMF | Lower | / | NS | NS | / |
| Tieland et al | Upper | / | NS | / | / |
| Ex + NuP + NuVM | Lower | / | NS | / | / |
| Ikeda et al | Upper | / | NS for rowing | / | / |
| Ex + NuP | Lower | / | Ex + NuP: significantly improved leg press | / | / |
| / | rate (2.7%±12.5%) and knee extension rate (−0.8%±18.2%) | ||||
| NS for hip abduction | / | / | |||
| Chin A Paw et al | Upper | / | NS | / | / |
| Ex + NuP + NuVM | Lower | / | NS | / | / |
| Rydwik et al | Upper | / | Ex + NuAd (mean change =1.7 kg [CI =0.04; 3.4]) and Ex (mean change =1.8 kg [CI =0.8; 2.8]): change significantly improved | / | NS |
| Lower | / | NS in shoulder | / | NS | |
| Kwon et al | Upper | / | Ex + NuAd: NS | / | Ex: NS |
| Ng et al | Lower | NS | Significantly improved change compared to control group (mean change =0.02 kg [CI =−1.08; 1.12]) | / | Significantly improved change compared to control group (mean change = −0.24 kg [CI = −1.34; 0.87]) |
| Kenny et al | Upper | / | NS | / | / |
| Hennessey et al | Lower | / | Hor | / | / |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05;
P<0.01;
P<0.001.
Abbreviations: DXA, dual X-ray absorptiometry; BIA, bioelectrical impedance analysis; FFM, fat-free mass; m, months; FU, follow-up; Hor, hormone; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuMF, nutritional supplementation of MFGM; PS, psychosocial intervention; NS, no significant difference; /, not available; kg, kilogram; CI, 95% confidence interval; SD, standard deviation.
Gait speed and physical activity
| Study | 3 months before end of intervention | Post-intervention (0 m) | 3–4 m FU | 6 m FU | 9 m FU |
|---|---|---|---|---|---|
| Kim et al | / | Ex + NuMF (% change =14.7±4.1) (CI =6.4; 23.1): change significantly improved | NS | / | / |
| Tieland et al | / | NS | / | / | / |
| Rydwik et al | / | NS | / | NS | / |
| Kwon et al | / | NS | / | NS | / |
| Chin A Paw et al | / | Ex + NuP + NuVM or Ex (0.06±0.1): significantly improved | / | / | / |
| Kenny et al | / | NS | / | / | / |
| Ng et al | NS | NS | / | NS | / |
| Kenny et al | / | NS | / | / | / |
| Rydwik et al | / | Ex and Ex + NuAd: change significantly improved | / | Ex: change significantly improved | / |
| Ng et al | NS | NuP + NuVM (mean change =96.2 [CI =57.8; 134.7]): change significantly improved | / | NuP + NuVM (mean change =110.1 [CI =71.9; 148.2]): significantly improved | / |
| Tarazona-Santabalbina et al | / | Ex + NuAd + NuVM (485.6±98.1): significantly improved | / | / | / |
| Ikeda et al | / | NS | / | / | / |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05;
P<0.01;
P<0.001.
Abbreviations: m, months; FU, follow-up; Hor, hormone; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuMF, nutritional supplementation of milk fat globule membrane; PS, psychosocial intervention; NS, no significant difference; /, not available; kg, kilogram; CI, 95% confidence interval; SD, standard deviation.
Functional abilities and physical functioning
| Study | 3 months before end of intervention | Post-intervention (0 m) | 3–4 m FU | 6 m FU | 9 m FU |
|---|---|---|---|---|---|
| Ng et al | NS | NS | / | NS | / |
| NS | NS | / | NS | / | |
| Chan et al | / | NS | NS | / | NS |
| Chin A Paw et al | / | NS | / | / | / |
| Tarazona-Santabalbina et al | / | ADL: Ex + NuAd + NuVM (91.6±8.0): significantly improved | / | / | / |
| SPPB | / | NS | / | / | / |
| SPPB | / | Ex + NuVM + Hor (10.7±1.9): significantly improved | / | / | / |
| SPPB | / | Ex + NuAd + NuVM (9.5±1.8): significantly improved | / | / | / |
| PPT | / | Ex + NuAd + NuVM (23.5±5.9): significantly improved | / | / | / |
| Tinetti | / | Ex + NuAd + NuVM (24.5±4.4): significantly improved | / | / | / |
| Performance score | / | Ex and Ex + NuP + NuVM significantly improved | / | / | / |
| Fitness score | / | NS: Ex and Ex + NuP NuVM NS different compared to NuP + NuVM or control group | / | / | / |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05;
P<0.01;
P<0.001.
Abbreviations: FU, follow-up; TUG, timed up and go test; Hor, hormone; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; PS, psychosocial intervention; NS, no significant difference; /, not available; s, seconds; CI, 95% confidence interval; SD, standard deviation.
Muscle power
| Study | Post-intervention (0 m) | 3 m FU | 9 m FU |
|---|---|---|---|
| Chan et al | NS | Ex + NuAD + PS and PS (2.71±6.08 kg): significantly improved | Ex + NuAD + PS and PS (−3.52±9.65 kg): significantly improved |
| Kenny et al | NS | / | / |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05.
Abbreviations: m, months; FU, follow-up; Hor, hormone; Ex, exercise intervention; NuVM, nutritional supplementation of vitamins and minerals; PS, psychosocial intervention; NS, no significant difference; /, not available; kg, kilogram; SD, standard deviation.
Gait ability, balance, functional lower extremity strength, falls
| Study | 3 months before end of intervention | Post-intervention (0 m) | 3–4 m FU | 6 m FU | 9 m FU |
|---|---|---|---|---|---|
| Kim et al | / | Ex + NuMF (% change =−14.4±2.0) | NS | / | / |
| Rydwik et al | / | NS | / | NS | / |
| Kenny et al | / | NS | / | / | / |
| Ikeda et al | / | NS | / | / | / |
| Rydwik et al | / | NS (modified figure eight) | / | NS | / |
| Ikeda et al | / | Ex + NuP: functional reach test improvement rate significantly improved | / | / | / |
| Chan et al | / | NS (single leg stance) | NS | / | NS |
| Kenny et al | / | NS (singe leg stance) | / | / | / |
| Rydwik et al | / | NS (tandem stance) | / | NS | / |
| / | NS (single leg stance) | / | NS | / | |
| Kwon et al | / | NS (stork stance) | / | NS | / |
| Chin A Paw et al | / | NS (tandem stance) | / | / | / |
| / | Ex + NuP + NuVM and Ex (4 [−7; 17]): change in score for balancing on balance board significantly improved | / | / | / | |
| Tarazona-Santabalbina et al | NS (Tinetti balance index) | / | / | / | |
| Rydwik et al | / | NS | / | NS | / |
| Chin A Paw et al | / | Ex + NuP + NuVM and Ex (−2.3 s for chair stand [−7.7; 1.4]): change significantly improved | / | / | / |
| Kenny et al | / | NS | / | / | / |
| Tieland et al | / | NS | / | / | / |
| Ng et al | NS | NS | / | NS | / |
| Tarazona-Santabalbina et al | / | NS | / | / | / |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05;
P<0.001.
Abbreviations: FU, follow-up; SPPB, short physical performance test; PPT, physical performance test; Hor, hormone; Ex, exercise intervention; Cog, cognitive intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NuMF, nutritional supplementation of milk fat globule membrane; PS, psychosocial intervention; NS, no significant difference; /, not available; s, seconds; CI, 95% confidence interval; SD, standard deviation.
Cognitive status
| Study | Post-intervention (0 m) |
|---|---|
| van de Rest | Episodic memory: NS |
| Attention and working memory: NS | |
| Information processing speed | |
| NuP + NuVM (-0.23±0.19) | |
| Executive functioning: NS |
Notes: Values are (mean ± SD) or (median [10th–90th percentile]) unless otherwise indicated.
P<0.05.
Abbreviations: Ex, exercise intervention; NuVM, nutritional supplementation of vitamins and minerals; NuP, nutritional supplementation of proteins; NS, no significant difference; SD, standard deviation.